IP Library Granted Patent US 7,608,607
Granted Patent B2
US 7,608,607 · App. 12/356,943 · Granted Oct 27, 2009

Pharmaceutical composition

Assignee: CPEX Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,608,607
App. No.
12/356,943
Granted
Oct 27, 2009
Kind
B2
Abstract

A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.

Claims (15)

1. A method for maintaining a therapeutically effective concentration of testosterone in the blood serum of a male for treating hypogonadism which comprises transdermally delivering to the male by applying to the skin a composition which is in the form of a topical gel, which has a viscosity of about 500 to about 20,000 cps and a pH of about 3 to about 9, and comprises: (A) about 0.1 to about 5 wt. % of testosterone; (B) about 0.5 to about 15 wt. % of oxacyclohexadecan-2-one; (C) about 0.1 to about 10 wt. % of a thickening agent; (D) a mixture of solvents which include: (i) about 60 to about 75 wt. % of ethanol or isopropanol; and (ii) propylene glycol and glycerin as co-solvents.

2. The method of claim 1 further comprising polyethylene glycol.

3. The method of claim 2 wherein the polyethylene glycol ranges from about 0.001 to about 5 wt. %.

4. The method of claim 1 wherein the thickening agent ranges from about 1 to about 6 wt. %.

5. The method of claim 1 wherein said composition is maintained on said skin for a period of time sufficient for delivery of the testosterone to the body of the male and is applied to the skin in the form of a unit dose which contains about 1 to about 300 mg of testosterone and such that, following a single application of the unit dose to the skin, the amount of circulating testosterone (AUC 0-24 ) in the blood serum of the male achieved in the 24-hour period following the application is about 100 to about 35,000 ngh/dL greater than the amount of circulating testosterone (AUC 0-24 ) in the blood serum of the male than would have been achieved in the same 24-hour period had the dose not been administered.

6. The method of claim 1 wherein the viscosity ranges from about 1,000 cps to about 9,000 cps.

7. The method of claim 6 wherein the viscosity ranges from about 2,000 cps to about 8,000 cps.

8. The method of claim 7 wherein the viscosity ranges from about 3,000 cps to about 7,000 cps.

9. The method of claim 1 wherein the pH ranges from about 4 to about 8.

10. A method for maintaining a therapeutically effective concentration of testosterone in the blood serum of a male for treating hypogonadism which comprises transdermally delivering to the male by applying to the skin a composition which is in the form of a topical gel, which has a viscosity of about 500 to about 20,000 cps and a pH of about 3 to about 9, and comprises: (A) about 0.1 to about 5 wt. % of testosterone; (B) about 0.5 to about 15 wt. % of oxacyclohexadecan-2-one; (C) about 0.1 to about 10 wt. % of a thickening agent; (D) a mixture of solvents which include: (i) about 60 to about 75 wt. % of ethanol or isopropanol; and (ii) propylene glycol and glycerin as co-solvents; and (E) about 0.001 to about 5 wt. % of polyethylene glycol as a crystallization inhibitor; wherein said composition is maintained on said skin for a period of time sufficient for delivery of the testosterone to the body of the male and is applied to the skin in the form of a unit dose which contains about 1 to about 300 mg of testosterone and such that, following a single application of the unit dose to the skin, the amount of circulating testosterone (AUC 0-24 ) in the blood serum of the male achieved in the 24-hour period following the application is about 100 to about 35,000 ngh/dL greater than the amount of circulating testosterone (AUC 0-24 ) in the blood serum of the male than would have been achieved in the same 24-hour period had the dose not been administered.

11. The method of claim 10 wherein the viscosity ranges from about 1,000 cps to about 9,000 cps.

12. The method of claim 11 wherein the viscosity ranges from about 2,000 cps to about 8,000 cps.

13. The method of claim 12 wherein the viscosity ranges from about 3,000 cps to about 7,000 cps.

14. The method of claim 10 wherein the pH ranges from about 4 to about 8.

15. The method of claim 10 wherein the thickening agent ranges from 1 to about 6 wt. %.

Assignments (5)
NOTICE OF ASSIGNMENT OF SECURITY INTEREST (INTELLECTUAL PROPERTY) Recorded Jun 30, 2017
From: THE BANK OF NEW YORK MELLON, AS EXISTING AGENT
To: GLAS AMERICAS LLC, AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 043065/0713 →
SECURITY INTEREST Recorded May 7, 2014
From: FCB I LLC
To: THE BANK OF NEW YORK MELLON
Reel/Frame 032843/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2011
From: CPEX PHARMACEUTICALS, INC.
To: FCB I LLC
Reel/Frame 026075/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2009
From: GYURIK, ROBERT J.
To: BENTLEY PHARMACEUTICALS, INC.
Reel/Frame 022924/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2009
From: BENTLEY PHARMACEUTICALS, INC.
To: CPEX PHARMACEUTICALS, INC.
Reel/Frame 022924/0083 →
Continuity (4)
Continuation 1193180900 · Oct 31, 2007
Continuation 1047372400
Provisional Application 6037410300 · Apr 19, 2002
Related Publication 20090124590A1 · May 14, 2009